Emergent BioSolutions Business Summary

Emergent BioSolutions Inc. (EBS) is a global life sciences company specializing in medical countermeasures (MCM) and public health preparedness. The company generates revenue through a dual-track model: high-value government procurement contracts for biodefense products and commercial sales of its market-leading opioid overdose reversal treatments. Its operations are divided into three primary segments: Commercial Products, led by the NARCAN (naloxone HCl) Nasal Spray and KLOXXADO franchises; MCM Products, which supplies vaccines and therapeutics for anthrax (CYFENDUS, BioThrax), smallpox (ACAM2000, TEMBEXA), and Ebola to the U.S. Strategic National Stockpile; and Services, providing contract development and manufacturing (CDMO) through its Bioservices portfolio. Emergent competes directly with specialized biodefense firms like SIGA Technologies and Bavarian Nordic, as well as diversified vaccine manufacturers such as Dynavax Technologies and Moderna. Within this landscape, Emergent maintains a unique position as a critical strategic partner to the U.S. government, underpinned by a multi-year transformation plan focused on debt reduction and core franchise optimization. Founded in 1998 by the late Fuad El-Hibri, the company is currently led by President and CEO Joseph C. Papa, a veteran executive with a pedigree from Bausch + Lomb, Perrigo, and Lannett. The senior leadership team includes Executive Vice President and CFO Richard S. Lindahl, formerly of CEB and Sprint, and Chief Medical Officer and Head of R&D Simon Lowry, M.D., who oversees the company’s scientific and clinical strategy. The Board of Directors is chaired by Zsolt Harsanyi, Ph.D., and includes notable members such as former HHS Secretary Louis W. Sullivan and biodefense expert Kathryn C. Zoon. Emergent’s institutional investor base is anchored by major financial entities including BlackRock, The Vanguard Group, and Oak Hill Advisors, reflecting its status as a pivotal player in the national security and public health infrastructure.